Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
David Tamborero(Universitat Pompeu Fabra), Etienne Rouleau(Inserm), Johan Hartman(Karolinska University Hospital), Frans L. Opdam(The Netherlands Cancer Institute), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Mariska Bierkens, Xenia Villalobos(Vall d'Hebron Hospital Universitari), Svetlana Bajalica‐Lagercrantz(Karolinska University Hospital), Jose‐Ezequiel Martín(University of Cambridge), Mary Kasanicki(University of Cambridge), Johan Lindberg(Karolinska Institutet), Alejandro Piris‐Giménez(Vall d'Hebron Hospital Universitari), Elena Chavarria(Vall d'Hebron Hospital Universitari), Lennart Blomqvist(Karolinska University Hospital), Gary J. Doherty(Cambridge University Hospitals NHS Foundation Trust), Claudio Nicotra(Institut Gustave Roussy), Peter Horak(German Cancer Research Center), Carlos López(Ministerio de Salud Pública), Michele Masucci(Karolinska Institutet), Susana Muñoz(Vall d'Hebron Institute of Oncology), Simon Kreutzfeldt(German Cancer Research Center), Richard F. Schlenk(German Cancer Research Center), Luigi De Petris(Karolinska University Hospital), Elena Garralda(Memorial Sloan Kettering Cancer Center), Jorrit Boekel(Science for Life Laboratory), Andreas Lundqvist(Karolinska Institutet), Petra Oberrauch(German Cancer Research Center), Maan Haj Rachid(Science for Life Laboratory), Elena Provenzano(University of Cambridge), Paola Gabaldi(Fondazione IRCCS Istituto Nazionale dei Tumori), Jonas Bergh(Karolinska Institutet), Gerrit A. Meijer(The Netherlands Cancer Institute), Päivi Östling(Karolinska Institutet), Irene Braña(Vall d'Hebron Institute of Oncology), Richard D. Baird(Cancer Research UK), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Shubha Anand(University of Cambridge), Judith Balmañà(Vall d'Hebron Hospital Universitari), Rodrigo Dienstmann(Universitat de Vic - Universitat Central de Catalunya), Rolf Lewensohn(Karolinska Institutet), Claes Karlsson(Karolinska University Hospital), Christophe Massard(Institut Gustave Roussy), Valentina Fornerone(Fondazione IRCCS Istituto Nazionale dei Tumori), P. Martin Romano(Institut Gustave Roussy), Danny Baars, Analía Azaro(Vall d'Hebron Hospital Universitari), Ionut G. Funingana(University of Cambridge), Jeffrey Yachnin(Karolinska University Hospital), A Forest(Institut Gustave Roussy), Maud Ngo Camus(Institut Gustave Roussy)
Cited by 89
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
|New England Journal of Medicine|2014|3.5k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k